Emerging microbiome-based therapies for atopic dermatitis: clinical insights and future development

Area of Science:

• Microbiome research
• Dermatology
• Immunology

Background:

• Current atopic dermatitis (AD) therapies primarily address inflammation, barrier dysfunction, and Staphylococcus aureus overgrowth.
• Environmental factors and microbiome dysbiosis are increasingly recognized as major drivers of AD pathogenesis.
• Existing treatments offer symptomatic relief but do not address underlying disease mechanisms.

Purpose of the Study:

• To review standard atopic dermatitis (AD) treatments and their limitations.
• To explore emerging microbiome-based therapies, specifically biotherapeutics (products with live microorganisms), for AD.
• To discuss the potential and challenges for biotherapeutics in the AD treatment market.

Main Methods:

• Literature review of current AD therapies.
• Analysis of emerging microbiome-based therapeutic strategies.
• Discussion of market and regulatory challenges for biotherapeutics.

Main Results:

• Standard AD treatments (emollients, corticosteroids, calcineurin inhibitors, systemic immunomodulators) provide symptomatic control but have limitations.
• Immune suppressive therapies are associated with side effects and do not address root causes.
• Microbiome-based therapies, particularly topical biotherapeutics, show potential for addressing dysbiosis and offering preventative benefits.

Conclusions:

• Future AD treatment strategies should expand beyond inflammation and barrier repair to include microbiome modulation and upstream environmental factors.
• Biotherapeutics represent a promising avenue for AD treatment, potentially offering disease prevention.
• Overcoming pharmaceutical, academic, and regulatory hurdles is crucial for the successful integration of biotherapeutics into AD management.